Pharmacological treatment of cognitive impairment in Multiple Sclerosis
A recent study published in CNS drugs ( Chen MH, Goverover Y, Genova HM, DeLuca J) concludes that there is not enough evidence to support the use of drug treatments to improve the cognitive function of people with MS.
Many contradictory findings were observed in this review, which may be due to possible unidentified variables of response to treatment moderation and/or lack of standardisation in assessment procedures.
There was also an over-reliance on statistical significance (most papers did not indicate the magnitude of treatment effects), which may not be clinically significant.
Higher quality randomised controlled trials are needed to establish the cognitive efficacy of drug treatments for MS-related cognitive dysfunction